KR20250119655A - 캄프토테신 화합물, 그의 제조방법 및 그의 응용 - Google Patents

캄프토테신 화합물, 그의 제조방법 및 그의 응용

Info

Publication number
KR20250119655A
KR20250119655A KR1020257024904A KR20257024904A KR20250119655A KR 20250119655 A KR20250119655 A KR 20250119655A KR 1020257024904 A KR1020257024904 A KR 1020257024904A KR 20257024904 A KR20257024904 A KR 20257024904A KR 20250119655 A KR20250119655 A KR 20250119655A
Authority
KR
South Korea
Prior art keywords
compound
group
formula
hydrogen
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257024904A
Other languages
English (en)
Korean (ko)
Inventor
치앙 티앤
이타오 장
유 미아오
보 왕
지안 예
샤오베이 왕
델리앙 리
펜 리
홍메이 송
Original Assignee
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 filed Critical 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드
Publication of KR20250119655A publication Critical patent/KR20250119655A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020257024904A 2021-02-05 2022-01-27 캄프토테신 화합물, 그의 제조방법 및 그의 응용 Pending KR20250119655A (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
CN202110159956.6 2021-02-05
CN202110159956 2021-02-05
CN202110533304 2021-05-17
CN202110533304.4 2021-05-17
CN202110718245 2021-06-28
CN202110718245.8 2021-06-28
CN202110936768.X 2021-08-16
CN202110936768 2021-08-16
CN202111355330.9 2021-11-16
CN202111355330 2021-11-16
KR1020237025527A KR20230142710A (ko) 2021-02-05 2022-01-27 캄프토테신 화합물, 그의 제조방법 및 그의 응용
PCT/CN2022/074328 WO2022166762A1 (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237025527A Division KR20230142710A (ko) 2021-02-05 2022-01-27 캄프토테신 화합물, 그의 제조방법 및 그의 응용

Publications (1)

Publication Number Publication Date
KR20250119655A true KR20250119655A (ko) 2025-08-07

Family

ID=82741966

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257024904A Pending KR20250119655A (ko) 2021-02-05 2022-01-27 캄프토테신 화합물, 그의 제조방법 및 그의 응용
KR1020257024905A Pending KR20250120438A (ko) 2021-02-05 2022-01-27 캄프토테신 화합물, 그의 제조방법 및 그의 응용
KR1020237025527A Pending KR20230142710A (ko) 2021-02-05 2022-01-27 캄프토테신 화합물, 그의 제조방법 및 그의 응용

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257024905A Pending KR20250120438A (ko) 2021-02-05 2022-01-27 캄프토테신 화합물, 그의 제조방법 및 그의 응용
KR1020237025527A Pending KR20230142710A (ko) 2021-02-05 2022-01-27 캄프토테신 화합물, 그의 제조방법 및 그의 응용

Country Status (9)

Country Link
US (2) US20240158410A1 (https=)
EP (3) EP4628165A3 (https=)
JP (3) JP7821188B2 (https=)
KR (3) KR20250119655A (https=)
CN (3) CN120058723A (https=)
AU (1) AU2022216696A1 (https=)
CA (1) CA3209426A1 (https=)
MX (1) MX2023008716A (https=)
WO (1) WO2022166762A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023551355A (ja) 2020-09-30 2023-12-08 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド 抗腫瘍化合物並びにその調製方法及び使用
US20250276078A1 (en) * 2020-10-12 2025-09-04 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin Derivative And Ligand-drug Conjugate Thereof
EP4628165A3 (en) * 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
JP2024532768A (ja) * 2021-08-19 2024-09-10 ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド カンプトテシン誘導体、その薬物組成物およびその応用
CN118119594A (zh) * 2021-10-26 2024-05-31 上海弼领生物技术有限公司 一种喜树碱类衍生物中间体、其制备方法和用途
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN118696048A (zh) * 2022-05-09 2024-09-24 同宜医药（苏州）有限公司 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用
JP2025515988A (ja) 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
IL318296A (en) 2022-07-15 2025-03-01 Genequantum Healthcare Suzhou Co Ltd Anti-TROP2 antibody and its conjugate
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
US20240116945A1 (en) * 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
CN121064210A (zh) * 2022-09-09 2025-12-05 杭州爱科瑞思生物医药有限公司 喜树碱-7-乙基胺衍生物及其制备方法和应用
KR20250069963A (ko) * 2022-09-30 2025-05-20 베이진 스위찰랜드 게엠베하 엑사테칸 유사체의 리간드-약물 접합체 및 이의 의학적 용도
WO2024078449A1 (en) 2022-10-09 2024-04-18 LaNova Medicines Limited Compounds, compositions and methods
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2024114318A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
CN116870187A (zh) * 2022-12-29 2023-10-13 杭州爱科瑞思生物医药有限公司 N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物
CN116712562A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物
CN116712563A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-卤代烷基取代的喜树碱衍生物的抗体偶联药物
EP4655006A2 (en) * 2023-01-25 2025-12-03 Immunome, Inc. Exatecan immunoconjugates
CN119630672B (zh) * 2023-02-23 2026-01-30 一线医药（杭州）有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
TW202502774A (zh) * 2023-03-01 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種茚并［１，２－ｂ］喹啉－１０，１３－二酮衍生物的製備方法
WO2024208314A1 (zh) * 2023-04-07 2024-10-10 长春金赛药业有限责任公司 喜树碱衍生物、药物组合物及其制备方法和应用
CN116478051B (zh) * 2023-04-13 2024-06-21 戊言医药科技（上海）有限公司 一种贝洛替康盐酸盐及其关键中间体的制备方法
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
WO2024227439A1 (zh) * 2023-05-04 2024-11-07 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
CN117417346B (zh) * 2023-09-11 2025-07-25 常州合全药业有限公司 喜树碱类衍生物的制备方法
KR20250059577A (ko) 2023-10-24 2025-05-07 삼성디스플레이 주식회사 표시 장치
TW202527997A (zh) * 2023-11-15 2025-07-16 大陸商四川科倫博泰生物醫藥股份有限公司 靶向ｅｇｆｒ／ｃ—ｍｅｔ之抗體—藥物結合物以及其製備方法及用途
CN120058720A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-含羟胺结构取代的烷基喜树碱衍生物的制备及其应用
CN120058721A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-氟烷基取代的喜树碱衍生物的制备及其应用
WO2025162049A1 (zh) * 2024-02-02 2025-08-07 长春金赛药业有限责任公司 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用
WO2025242090A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 喜树碱衍生物及其中间体的制备方法
WO2026046398A1 (en) * 2024-08-30 2026-03-05 Hansoh Bio Llc Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
DE69623961T2 (de) * 1995-06-21 2003-05-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Paris Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendungals arzneimittel und diese enthaltende pharmazeutische zusammenfassungen
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
CN100408582C (zh) * 2004-02-12 2008-08-06 中国人民解放军第二军医大学 高喜树碱类化合物及其制备方法和用途
JP2019515025A (ja) * 2016-04-04 2019-06-06 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー トポイソメラーゼ毒
CN110891942B (zh) * 2017-07-14 2022-06-07 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
CN119241554A (zh) * 2017-12-15 2025-01-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
BR112020020466A2 (pt) 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
WO2020063676A1 (zh) * 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CA3114474A1 (en) * 2018-09-30 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
MX2021011812A (es) * 2019-03-29 2021-10-22 Medimmune Ltd Compuestos y conjugados de estos.
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN110357897A (zh) * 2019-07-26 2019-10-22 上海健康医学院 一种具有抗肿瘤活性的喜树碱衍生物及其制备方法和应用
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
JP7781064B2 (ja) * 2020-01-22 2025-12-05 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途
AU2021289927A1 (en) * 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
JP7753372B2 (ja) * 2020-10-12 2025-10-14 シーチュアン バイリ ファーム シーオー． エルティーディー 重水素化カンプトテシン系誘導体及びその抗体薬物複合体
EP4628165A3 (en) * 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN117255790A (zh) * 2021-06-02 2023-12-19 四川科伦博泰生物医药股份有限公司 一类化学偶联连接子及其用途
JP2024521629A (ja) * 2021-06-02 2024-06-04 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗体薬物コンジュゲート、及びその調製方法及びその使用
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN117567487A (zh) * 2023-11-27 2024-02-20 金宏气体股份有限公司 双核Ag(I)配合物晶体、制备方法、负载物、装置及应用

Also Published As

Publication number Publication date
JP2025160317A (ja) 2025-10-22
EP4628165A2 (en) 2025-10-08
CN120058723A (zh) 2025-05-30
JP2024506819A (ja) 2024-02-15
EP4289851A4 (en) 2025-10-15
MX2023008716A (es) 2023-08-02
CN117567478A (zh) 2024-02-20
CN117567478B (zh) 2025-03-21
EP4613335A3 (en) 2025-12-10
KR20230142710A (ko) 2023-10-11
EP4628165A3 (en) 2026-03-11
US20240158410A1 (en) 2024-05-16
JP7821188B2 (ja) 2026-02-26
JP2025160318A (ja) 2025-10-22
KR20250120438A (ko) 2025-08-08
CN116829561A (zh) 2023-09-29
US20250346606A1 (en) 2025-11-13
EP4613335A2 (en) 2025-09-10
WO2022166762A1 (zh) 2022-08-11
AU2022216696A1 (en) 2023-08-17
EP4289851A1 (en) 2023-12-13
CA3209426A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
JP7821188B2 (ja) カンプトテシン化合物、その調製方法、及びその適用
JP2025515988A (ja) カンプトテシン化合物、その調製方法及びその使用
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
CN101495486B (zh) 具有抗肿瘤活性的喜树碱衍生物
JP2023552610A (ja) 新規カンプトテシン誘導体、それを含む組成物およびその使用
CN116113416B (zh) 四环类衍生物、其制备方法和其医药上的用途
CN116157400B (zh) 杂环类衍生物及其制备方法和用途
WO2024078581A1 (en) Selective bcl-xl protac compounds and uses thereof
WO2025036489A1 (zh) 一种氰基芳香环衍生物及其在医药上的应用
HK40101679A (zh) 喜树碱类化合物及其制备方法和应用
EP4219453A1 (en) Pyrazole compound and preparation method therefor and use thereof
HK40101679B (zh) 喜树碱类化合物及其制备方法和应用
WO2025124555A1 (en) Ligand-drug conjugate of camptothecin analogs and use thereof
US20260102507A1 (en) Camptothecin derivative for treating or preventing cancer and antibody-drug conjugate thereof
RU2858136C2 (ru) Новое производное камптотецина, композиция, включающая его, и его применение
CN120858098A (zh) 稠环化合物及其制备方法和应用
CA3289444A1 (en) Kras inhibitor compound, pharmaceutical composition thereof, and use thereof
CN120053678A (zh) 一种高喜树碱类抗体偶联药物、其制备方法及应用
HK1135692B (en) Camptothecin derivatives with antitumor activity
HK1135692A1 (en) Camptothecin derivatives with antitumor activity
HK1135693B (en) Camptothecin derivatives with antitumor activity
HK1135693A1 (en) Camptothecin derivatives with antitumor activity

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)